Septic Shock
Research on septic and vasodilatory shock, including vasopressor therapy, hemodynamic support, and critical care interventions for distributive shock states.
Quick Answer
What it is
Research on septic and vasodilatory shock, including vasopressor therapy, hemodynamic support, and critical care interventions for distributive shock states.
Key findings
- Grade A: Mean Arterial Pressure Response (Angiotensin II)
- Grade A: Vasopressor Dose Reduction (Angiotensin II)
- Grade A: 28-Day Mortality (Angiotensin II)
Safety
- May reduce catecholamine toxicity.
ℹ️ Quick Facts
Quick Facts: Septic Shock
- Supplements Studied:1
1 supps · 4 outcomes
Detailed Outcomes
A
Mean Arterial Pressure Response
ATHOS-3 (n=321): 70% achieved MAP ≥75 mmHg or ≥10 mmHg increase at 3h vs 23% placebo (P<0.001). 45% absolute increase in responders. Effective in catecholamine-resistant shock.
large↑Improves
A
Vasopressor Dose Reduction
ATHOS-3: Significant reduction in background vasopressor requirements. Catecholamine-sparing effect allows reduction of norepinephrine doses. May reduce catecholamine toxicity.
moderate↓Improves
A
28-Day Mortality
ATHOS-3: No significant mortality difference (46% vs 54%, P=0.12). Study not powered for mortality. Post-hoc AKI/RRT subgroup: 53% vs 30% survival (P=0.012). Mortality benefit uncertain.
none
A
Thromboembolic Events
SAFETY CONCERN: ATHOS-3: 13% vs 5% thromboembolic events (DVT, arterial). Major imbalance in DVT. Concurrent DVT prophylaxis required. Systematic review (n=1,461): Similar rates in larger observational data (8.8% vs 9.4% VTE).
moderate↓Worsens